Alnylam Pharma (ALNY) Tops Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alnylam Pharmaceuticals (ALNY) PT Raised to $86 at Jefferies
August 5, 2016 9:30 AM EDTJefferies analyst Gena Wang reiterated a Buy rating and raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ti $86.00 (from $80.00) following Q2 update which highlighted progress in clinical programs.
Wang commented, "Following recent data updates (TTR programs, CC5 and fitusiran), we continue to... More
